Lynwood Capital Management’s Briacell Therapeutics BCTX Stock Holding History

Lynwood Capital Management’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$4.57M	Buy	10,652 +114	+1%	+$62.8K	27.08%	1
2023 Q4	$9.25M	Sell	10,538 -12	-0.1%	-$8.61K	40.71%	1
2023 Q3	$9.89M	Sell	10,550 -9	-0.1%	-$8.81K	26.01%	1
2023 Q2	$10.2M	Buy	10,559 +359	+4%	+$354K	12.88%	1
2023 Q1	$11.4M	Hold	10,200	–	–	10.29%	1
2022 Q4	$6.69M	Buy	10,200 +2,213	+28%	+$1.87M	8.04%	1
2022 Q3	$6.73M	Buy	7,987 +3,887	+95%	+$3.9M	7.35%	1
2022 Q2	$3.55M	Sell	4,100 -900	-18%	-$889K	3.96%	3
2022 Q1	$7.61M	Sell	5,000 -233	-4%	-$276K	8.16%	1
2021 Q4	$6.5M	Buy	+5,233	New	+$6.86M	6.22%	2

Other funds holding BCTX

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

OBWG

Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

STA

Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Lynwood Capital Management's BCTX Position: Q1 2024 in Review

Lynwood Capital Management increased its Briacell Therapeutics (BCTX) stake by 1.1% in Q1 2024, buying an estimated $62.8K and bringing the position to 10,652 shares worth $4.57M. The position accounts for 27.08% of the portfolio, ranked #1.

Lynwood Capital Management first reported a position in BCTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $11.4M in Q1 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q1 2024.

Lynwood Capital Management held 10,652 shares of Briacell Therapeutics worth $4.57M as of Q1 2024.
Lynwood Capital Management bought 114 Briacell Therapeutics shares in Q1 2024, an estimated $62.8K.
Briacell Therapeutics made up 27.08% of Lynwood Capital Management's portfolio in Q1 2024, its #1 holding.
Lynwood Capital Management first reported a position in Briacell Therapeutics in Q4 2021 and has held it in 10 quarters since.
Lynwood Capital Management's Briacell Therapeutics position peaked at $11.4M in Q1 2023.
19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2024.

Based on Lynwood Capital Management's 13F filing for Q1 2024, filed 10 May 2024.